Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCELERATE evacetrapib outcomes study in high-risk vascular disease
NL-OMON39898Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in atherosclerotic disease, acute coronary syndrome (ACS), atherosclerotic cerebrovascular disease and 3 more comparing Evacetrapib with Placebo (2 arms). Primary endpoint: Major adverse cardiovascular events composite. Started May 2013; status: active, not recruiting.
02
Drugs
evacetrapib
03
Conditions
atherosclerotic diseaseacute coronary syndrome (ACS)atherosclerotic cerebrovascular diseasearteriosclerosis obliteranscoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON39898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39898.